Zacks Investment Research on MSN
Merck's ADC candidate meets goals in endometrial cancer study
Merck MRK announced that the pivotal phase III TroFuse-005 study, which evaluated its pipeline candidate, sacituzumab ...
Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial ...
The TroFuse-005 trial involved 776 patients with endometrial cancer whose disease worsened after receiving both platinum ...
Merck & Co. Inc. (NYSE:MRK) is one of the best low risk stocks to buy in 2026. On May 18, Merck announced that its pivotal ...
The TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) demonstrated a statistically significant ...
Earlier this week, Merck announced that its pivotal Phase 3 TroFuse-005 trial showed sacituzumab tirumotecan significantly ...
The TROP2-directed antibody-drug conjugate demonstrated superior efficacy over physician’s choice of chemotherapy in patients previously treated with platinum-based therapy and immunotherapy.
SurvivorNet on MSN
Endometrial cancer: Why the patient’s voice needs to be part of the treatment plan
Patient preference is an important part of cancer treatment planning, but new research suggests that many women facing ...
Merck-Kelun ADC boosts survival in phase 3 endometrial cancer, stokes TROP2 race Kelun partnerships sac-TMT shows survival ...
Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results